Trial Profile
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 28 Mar 2024
Price :
$35
*
At a glance
- Drugs Sotagliflozin (Primary)
- Indications Cardiovascular disorders; Myocardial infarction; Renal failure; Stroke; Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms SCORED
- Sponsors Lexicon Pharmaceuticals; Sanofi
- 25 Mar 2024 According to a Lexicon Pharmaceuticals media release, four data including results from a post-hoc evaluation of the efficacy of sotagliflozin in reducing stroke events in patients with type 2 diabetes, chronic kidney disease (CKD) from this study will be presented at the American College of Cardiology 73rd Annual Scientific Session & Expo being held April 6 - 8, 2024 in Atlanta, Georgia.
- 13 Nov 2023 Results evaluating the time to clinical benefit for HF-related events and MACE with sotagliflozin, presented at the American Heart Association Scientific Sessions 2023
- 12 Nov 2023 According to a Lexicon Pharmaceuticals media release, data were shared in an oral presentation by Rahul Aggarwal, M.D., Brigham and Women's Hospital, Boston, Massachusetts, at the American Heart Association (AHA) Scientific Sessions 2023 in Philadelphia, Pennsylvania.